Latest Content

The new platform offers coupon-driven discounts on dozens of high-cost brand name drugs, while raising new questions about eligibility, access, and how savings are applied.

The commercial PBM model is confronting structural strain as market forces—not regulation—begin to expose the fragility of high-rebate pricing economics.

A four-pillar strategy to help ensure both, as copay programs face mounting payer pressure and misuse in 2026.

In today’s Pharma Pulse, the FTC secures a multi-billion-dollar settlement against the "rebate trap," while Congress provides long-term certainty for the digital health revolution.

Policy shifts bring meaningful improvements for some—but looming coverage losses and rising premiums threaten to erase those gains.

A landmark FTC settlement requires Express Scripts to overhaul formulary and rebate practices, boosting price transparency in the process.

CMS’s Globe and Guard models extend MFN pricing into Medicare Part B and Part D, signaling a sweeping shift in US drug pricing policy.

At Trade & Channel Strategies, industry executives explored evolving channel models, serialization challenges, generics and biosimilars, and the strategies shaping pharma's future.

In today’s Pharma Pulse, the biopharma landscape enters a transformative phase as the US signs landmark PBM reforms into law, while Novartis braces for the largest patent expiration cycle in its history.

In the final part of his Pharma Commerce video interview, Joe Hudicka, entrepreneur and supply chain expert, outlines how real-time AI signal sharing across supply chain partners can help pharma companies anticipate demand shifts, reduce shortages, and respond faster to pandemics and geopolitical disruptions.

In today’s Pharma Pulse, AstraZeneca faces a complete response letter for its self-injectable lupus drug, while the EMA gives the green light to a historic wave of new therapies for MASH, rare diseases, and postmenopause.

The acquisition expands ORBIS’ manufacturing capacity and technical expertise in reusable plastic pallets, lids, and trays, enabling faster design, prototyping, and production for pharma and broader supply chain applications.

In the third part of his Pharma Commerce video interview, Joe Hudicka, entrepreneur and supply chain expert, explains why independent verification, validation, and human decision-making must stay central, as AI accelerates data processing and operational workflows across pharma supply chains.